Clariane SE

LSE:0OPS Stock Report

Market Cap: €657.8m

Clariane Valuation

Is 0OPS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0OPS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0OPS (€1.85) is trading below our estimate of fair value (€21.56)

Significantly Below Fair Value: 0OPS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0OPS?

Key metric: As 0OPS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0OPS. This is calculated by dividing 0OPS's market cap by their current revenue.
What is 0OPS's PS Ratio?
PS Ratio0.1x
Sales€5.17b
Market Cap€657.76m

Price to Sales Ratio vs Peers

How does 0OPS's PS Ratio compare to its peers?

The above table shows the PS ratio for 0OPS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.5x
CVSG CVS Group
0.9x5.5%UK£590.4m
SPI Spire Healthcare Group
0.6x6.0%UK£881.2m
MDC Mediclinic International
1.1x3.6%UK£3.7b
AMS Advanced Medical Solutions Group
3.5x16.8%UK£457.3m
0OPS Clariane
0.1x4.9%€657.8m

Price-To-Sales vs Peers: 0OPS is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (1.7x).

Price to Sales Ratio vs Industry

How does 0OPS's PS Ratio compare vs other companies in the European Healthcare Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
0OPS 0.1xIndustry Avg. 0.7xNo. of Companies9PS00.40.81.21.62+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0OPS is good value based on its Price-To-Sales Ratio (0.1x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is 0OPS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0OPS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.1x
Fair PS Ratio0.8x

Price-To-Sales vs Fair Ratio: 0OPS is good value based on its Price-To-Sales Ratio (0.1x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0OPS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.85
€2.04
+10.1%
12.6%€2.40€1.70n/a5
Nov ’25€2.06
€1.95
-5.5%
10.6%€2.20€1.70n/a4
Oct ’25€1.70
€1.95
+14.5%
10.6%€2.20€1.70n/a4
Sep ’25€1.98
€1.95
-1.3%
10.6%€2.20€1.70n/a4
Aug ’25€1.84
€2.35
+27.7%
6.4%€2.50€2.20n/a2
Jul ’25€1.86
€5.20
+180.0%
51.9%€7.90€2.50n/a2
Jun ’25€3.35
€3.83
+14.0%
63.1%€7.90€1.70n/a4
May ’25€2.28
€3.83
+67.7%
63.1%€7.90€1.70n/a4
Apr ’25€1.46
€4.50
+208.1%
56.6%€7.90€1.70n/a5
Mar ’25€1.90
€4.53
+138.7%
48.0%€7.90€2.50n/a6
Feb ’25€2.26
€5.31
+134.8%
52.3%€10.00€2.50n/a7
Jan ’25€2.41
€5.31
+119.9%
52.3%€10.00€2.50n/a7
Dec ’24€2.17
€6.14
+183.3%
43.7%€10.00€2.80n/a7
Nov ’24€3.59
€8.61
+139.5%
30.6%€12.00€5.00€2.067
Oct ’24€5.71
€10.44
+82.9%
18.6%€13.00€7.20€1.707
Sep ’24€6.19
€10.44
+68.7%
18.6%€13.00€7.20€1.987
Aug ’24€6.80
€11.48
+68.8%
25.5%€17.00€7.50€1.847
Jul ’24€6.69
€11.69
+74.7%
24.8%€17.00€7.50€1.867
Jun ’24€7.21
€11.69
+62.3%
24.8%€17.00€7.50€3.357
May ’24€7.87
€11.69
+48.6%
24.8%€17.00€7.50€2.287
Apr ’24€6.89
€15.31
+122.3%
54.6%€36.00€7.50€1.468
Mar ’24€7.48
€21.31
+184.8%
38.4%€36.00€9.00€1.908
Feb ’24€9.47
€23.56
+148.7%
35.0%€36.00€10.50€2.268
Jan ’24€10.12
€24.69
+144.0%
28.3%€36.00€14.00€2.418
Dec ’23€9.73
€24.69
+153.7%
28.3%€36.00€14.00€2.178
Nov ’23€10.01
€25.94
+159.1%
27.4%€36.00€14.00€3.598

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Arjo

SEK 9.3b

Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.

0HQ8

SEK 34.02

7D

0.4%

1Y

-6.6%

Centene

US$30.5b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

0HVB

US$61.32

7D

4.8%

1Y

-17.1%

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

0HG8

US$409.11

7D

2.1%

1Y

-14.2%